

OPAB priorities through 2025 (2.5 year period)

Ch 333 Rules review and revision
Angela Carter

Reassessment of synthetic Psilocybin products
Angela Carter

Species and substrate reassessment
Angela Carter

OPAB Strategic Plan Development for safety, affordability, and accessibility
Angela Carter

Define Safety, affordability and Accessibility
Angela Carter

Develop quantitative metrics for assessment of the 3 requirements
Angela Carter

Determine timeline, process, and dates for information submission to OHA to reach goal
Angela Carter

Strategic plan development facilitator? (Angie will follow in 11/21)
Review of other strategic plans (cannabis) for templating and direction
Angela Carter

Data collection on recent changes to city and county statutes and policies around allowing program activities within the areas
Angela Carter

Methods to assure equitable access in location and transportation to service centers
Angela Carter

Develop Mechanism to collect and analyze client-level data and integrate learning into OPAB and OHA work
Outsource data collection to a non-governmental independent agency that may garner funding for the development and implementation of data collection? Academic medical center? private research institutes?
OHA provide RFP for data collection and create MOU with stipulation to avoid financial COI?
Angela Carter

Develop mechanism to solicit feedback and information from providers, manufacturers, and service centers
Angela Carter

Board to Board agreements for dual-licensed providers (Psilocybin services has reached out to establish relationships)
Provider guidelines for dual-licensed providers
Angela Carter

Insurance coverage for providers, service centers, and manufacturers
Angela Carter

Definition and structure of Economic/Market place practices
Angela Carter

Development of an evaluation plan for the training programs based on client outcomes, accessibility and affordability
Angela Carter

Assuring Tribal access to services with ongoing consultation
Angela Carter

ongoing federal law review
Angela Carter

define parameters of laws and regulations to review and integrate
Angela Carter

FDA policy, FTC, Agricultural regs, Education, correlation to cannabis field laws, Center for Medicare and Medicaid Services, DEA and prescriber concerns
Angela Carter

How FDA potential future approval of Psilocybin and analogues may impact Oregon Psilocybin Services
Angela Carter

Meeting with US Attorney's office to discuss federal enforcement policies (after 2 years)
Angela Carter

Provide a robust regulatory scheme prior to approaching
Angela Carter

Provide programmatic results and data collected to demonstrate programmatic safety and efficacy
Angela Carter

Consider lessons learned on COLE Memo
Angela Carter

Consider Ogden memo from 2009
Angela Carter

Strategize on approach methods and relationship development
Angela Carter

Ongoing recommendations to OHA for statutory changes
Angela Carter

Psilocybin Research licensure considerations around market level products as well as synthetics
Angela Carter

Provider protections for dual-licensed providers
Angela Carter

Research subcommittee review of literature and data presentations
Angela Carter

October '22: Determine timeline, structure, definitions, and metrics that will guide the development of the strategic plan
Angela Carter

Equity Subcommittee ongoing recommendations and implementation
Angela Carter

Indigenous practitioner/Modalities subcommittee
Angela Carter

Ensuring Tribal access to services
Angela Carter